Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • tislelizumab-jsgr

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    EU flag

    EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

    The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

    - PMLiVE

    FDA unveils new voucher programme to accelerate drug review process

    The programme is designed to reduce the review time for companies supporting US national interests

    - PMLiVE

    BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

    Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

    - PMLiVE

    BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

    The aggressive form of lung cancer accounts for around 15% of all cases of the disease

    - PMLiVE

    BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

    Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

    - PMLiVE

    FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    The mosquito-borne viral disease has been reported across many popular travel destinations

    - PMLiVE

    Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

    The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

    - PMLiVE

    FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

    The company hopes the revised protocol will accelerate the development timeline of buntanetap

    - PMLiVE

    BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

    Approximately 27,000 cases of the disease were diagnosed in the US in 2024

    - PMLiVE

    BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

    Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

    - PMLiVE

    FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links